000132896 001__ 132896
000132896 005__ 20240229105038.0
000132896 0247_ $$2doi$$a10.1097/EDE.0000000000000795
000132896 0247_ $$2pmid$$apmid:29287053
000132896 0247_ $$2ISSN$$a1044-3983
000132896 0247_ $$2ISSN$$a1531-5487
000132896 037__ $$aDKFZ-2018-00538
000132896 041__ $$aeng
000132896 082__ $$a610
000132896 1001_ $$0P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aNiedermaier, Tobias$$b0$$eFirst author$$udkfz
000132896 245__ $$aDiagnostic Performance of One-off Flexible Sigmoidoscopy with Fecal Immunochemical Testing in a Large Screening Population.
000132896 260__ $$aPhiladelphia, Pa.$$bLippincott Williams & Wilkins$$c2018
000132896 3367_ $$2DRIVER$$aarticle
000132896 3367_ $$2DataCite$$aOutput Types/Journal article
000132896 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660051373_23715
000132896 3367_ $$2BibTeX$$aARTICLE
000132896 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132896 3367_ $$00$$2EndNote$$aJournal Article
000132896 520__ $$aFlexible sigmoidoscopy and fecal immunochemical tests are established diagnostic tests for colorectal cancer (CRC) screening and less invasive, less expensive, and easier to conduct than colonoscopy. However, little is known about their joint diagnostic performance compared with colonoscopy. We aimed to assess the expected diagnostic performance of joint use of flexible sigmoidoscopy and fecal immunochemical test.We assessed the overall and site-specific prevalences of colorectal neoplasms and the overall sensitivity, specificity, area under the receiver operating characteristics curve of a quantitative fecal immunochemical test (FOB Gold, Sentinel Diagnostics, Milano, Italy) among 3,466 participants in screening colonoscopy in Germany. Results were used to model the expected diagnostic performance of joint use of flexible sigmoidoscopy and fecal immunochemical testing.CRC and advanced adenomas were found in 29 (1%) and 354 (10%) participants, respectively. The area under the curve of fecal immunochemical testing for these outcomes could be raised from 96% to 100% and from 70% to 89%, respectively, by combining it with flexible sigmoidoscopy. At 90% specificity, sensitivity of fecal immunochemical testing would increase from 97% to 100% for CRC and from 40% to 79% for advanced adenomas.Combining flexible sigmoidoscopy and fecal immunochemical testing might strongly enhance diagnostic performance of each single test to a level close to the diagnostic performance of screening colonoscopy while avoiding many unnecessary colonoscopies.
000132896 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132896 588__ $$aDataset connected to CrossRef, PubMed,
000132896 7001_ $$0P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aWeigl, Korbinian$$b1$$udkfz
000132896 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b2$$udkfz
000132896 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000132896 773__ $$0PERI:(DE-600)2042095-X$$a10.1097/EDE.0000000000000795$$gVol. 29, no. 3, p. 397 - 406$$n3$$p397 - 406$$tEpidemiology$$v29$$x1044-3983$$y2018
000132896 909CO $$ooai:inrepo02.dkfz.de:132896$$pVDB
000132896 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)20dc4ad11ff465acf5b99f1e679e10b7$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132896 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4e98340e600f7411886c21c7b778d36$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132896 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132896 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132896 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132896 9141_ $$y2018
000132896 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000132896 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132896 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium
000132896 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPIDEMIOLOGY : 2015
000132896 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132896 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132896 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132896 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132896 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132896 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132896 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132896 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index
000132896 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences
000132896 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132896 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132896 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEPIDEMIOLOGY : 2015
000132896 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132896 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000132896 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x2
000132896 980__ $$ajournal
000132896 980__ $$aVDB
000132896 980__ $$aI:(DE-He78)C070-20160331
000132896 980__ $$aI:(DE-He78)L101-20160331
000132896 980__ $$aI:(DE-He78)G110-20160331
000132896 980__ $$aUNRESTRICTED